HRMY insider transaction filings
Harmony Biosciences Holdings, Inc. — 42 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-05-18. Screen HRMY transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-05-18 | 4 | Philip Ron M — Director | Grant/award (A): 21,872 (derivative) @ $0 | EDGAR |
| 2026-05-18 | 4 | Budur Kumar — CHIEF MEDICAL OFFICER | Option exercise (M): 18,750 @ $0 · Tax withholding (F): 8,882 @ $31.83 · Option exercise (M): 18,750 (derivative) @ $0 | EDGAR |
| 2026-05-18 | 4 | Sabater Juan A. — Director | Grant/award (A): 21,872 (derivative) @ $0 | EDGAR |
| 2026-05-18 | 4 | Reicin Glenn — CHIEF FINANCIAL OFFICER | Grant/award (A): 164,309 (derivative) @ $0 | EDGAR |
| 2026-05-18 | 4 | Szyper Linda M — Director | Grant/award (A): 21,872 (derivative) @ $0 | EDGAR |
| 2026-05-18 | 4 | Sender Gary — Director | Grant/award (A): 21,872 (derivative) @ $0 | EDGAR |
| 2026-05-18 | 4 | Graf R. Mark — Director | Grant/award (A): 21,872 (derivative) @ $0 | EDGAR |
| 2026-05-18 | 4 | Germano Geno J — Director | Grant/award (A): 21,231 (derivative) @ $0 | EDGAR |
| 2026-04-09 | 4 | Zaeske Adam H. — CHIEF COMMERCIAL OFFICER | Option exercise (M): 7,500 @ $0 · Tax withholding (F): 3,173 @ $27.62 · Option exercise (M): 7,500 (derivative) @ $0 | EDGAR |
| 2026-04-06 | 4 | Anastasiou Peter — CHIEF OPERATING OFFICER | Grant/award (A): 212,241 (derivative) @ $0 | EDGAR |
| 2026-04-06 | 4 | Ignelzi Troy A. — Director | Grant/award (A): 17,710 (derivative) @ $0 | EDGAR |
| 2026-01-28 | 4 | Kapadia Sandip — CHIEF FINANCIAL OFFICER | Sale (S): 3,746 @ $37.15 | EDGAR |
| 2026-01-26 | 4 | Zaeske Adam H. — CHIEF COMMERCIAL OFFICER | Grant/award (A): 56,900 (derivative) @ $0 · Grant/award (A): 16,200 (derivative) @ $0 | EDGAR |
| 2026-01-26 | 4 | Budur Kumar — CHIEF MEDICAL OFFICER | Option exercise (M): 2,188 @ $0 · Tax withholding (F): 1,153 @ $36.82 · Option exercise (M): 2,662 @ $0 · Tax withholding (F): 1,372 @ $36.82 · Grant/award (A): 42,600 (derivative) @ $0 · Grant/award (A): 12,200 (derivative) @ $0 · +2 more | EDGAR |
| 2026-01-26 | 4 | Serafin Andrew — CHIEF STRATEGY OFFICER | Option exercise (M): 2,500 @ $0 · Tax withholding (F): 1,116 @ $36.82 · Option exercise (M): 2,600 @ $0 · Tax withholding (F): 1,126 @ $36.82 · Grant/award (A): 42,600 (derivative) @ $0 · Grant/award (A): 12,200 (derivative) @ $0 · +2 more | EDGAR |
| 2026-01-26 | 4 | Kapadia Sandip — CHIEF FINANCIAL OFFICER | Option exercise (M): 3,813 @ $0 · Tax withholding (F): 2,239 @ $36.82 · Option exercise (M): 4,725 @ $0 · Tax withholding (F): 2,553 @ $36.82 · Grant/award (A): 42,600 (derivative) @ $0 · Grant/award (A): 12,200 (derivative) @ $0 · +2 more | EDGAR |
| 2026-01-26 | 4 | Dayno Jeffrey M. — PRESIDENT, CEO, Director | Option exercise (M): 10,500 @ $0 · Tax withholding (F): 4,785 @ $36.82 · Option exercise (M): 13,000 @ $0 · Tax withholding (F): 5,654 @ $36.82 · Grant/award (A): 184,600 (derivative) @ $0 · Grant/award (A): 52,900 (derivative) @ $0 · +2 more | EDGAR |
| 2026-01-20 | 4 | Kapadia Sandip — CHIEF FINANCIAL OFFICER | Sale (S): 20,961 @ $35.92 | EDGAR |
| 2025-12-17 | 4 | Dayno Jeffrey M. — PRESIDENT, CEO, Director | Option exercise (M): 20,000 @ $8.22 · Sale (S): 20,000 @ $40.11 · Sale (S): 5,933 @ $40.11 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2025-12-09 | 4 | Kapadia Sandip — CHIEF FINANCIAL OFFICER | Option exercise (M): 20,000 @ $29.03 · Sale (S): 20,000 @ $39.54 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2025-11-25 | 4 | Kapadia Sandip — CHIEF FINANCIAL OFFICER | Sale (S): 3,427 @ $35 | EDGAR |
| 2025-10-02 | 4 | Kapadia Sandip — CHIEF FINANCIAL OFFICER | Option exercise (M): 45,000 @ $0 · Tax withholding (F): 24,039 @ $27.56 · Option exercise (M): 45,000 (derivative) @ $0 | EDGAR |
| 2025-09-02 | 4 | Valor IV Pharma Holdings, LLC — 10% owner Valor Management L.P. — 10% owner Valor Equity Capital IV LLC — 10% owner Valor Equity Associates IV L.P. — 10% owner VALOR EQUITY PARTNERS IV L.P. — 10% owner VALOR EQUITY PARTNERS IV-A L.P. — 10% owner VALOR EQUITY PARTNERS IV-B L.P. — 10% owner Gracias Antonio J. — Director, 10% owner Sabater Juan A. — Director, 10% owner | Other (J): 6,618,033 | EDGAR |
| 2025-08-19 | 4 | Kapadia Sandip — CHIEF FINANCIAL OFFICER | Sale (S): 21,573 @ $36.50 | EDGAR |
| 2025-05-16 | 4 | Sabater Juan A. — Director | Grant/award (A): 14,522 (derivative) @ $0 | EDGAR |
| 2025-05-16 | 4 | Philip Ron M — Director | Grant/award (A): 14,522 (derivative) @ $0 | EDGAR |
| 2025-05-16 | 4 | Anastasiou Peter — Director | Grant/award (A): 14,522 (derivative) @ $0 | EDGAR |
| 2025-05-16 | 4 | Szyper Linda M — Director | Grant/award (A): 14,522 (derivative) @ $0 | EDGAR |
| 2025-05-16 | 4 | Sender Gary — Director | Grant/award (A): 14,522 (derivative) @ $0 | EDGAR |
| 2025-05-16 | 4 | Gracias Antonio J. — Director | Grant/award (A): 14,522 (derivative) @ $0 | EDGAR |
| 2025-05-16 | 4 | Graf R. Mark — Director | Grant/award (A): 14,522 (derivative) @ $0 | EDGAR |
| 2025-05-09 | 4 | Budur Kumar — CHIEF MEDICAL OFFICER | Option exercise (M): 18,750 @ $0 · Tax withholding (F): 8,869 @ $29.86 · Option exercise (M): 18,750 (derivative) @ $0 | EDGAR |
| 2025-04-16 | 4 | Zaeske Adam H. — CHIEF COMMERCIAL OFFICER | Grant/award (A): 100,000 (derivative) @ $0 · Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-04-04 | 4 | Philip Ron M — Director | Grant/award (A): 14,077 (derivative) @ $0 | EDGAR |
| 2025-04-03 | 4 | Kapadia Sandip — CHIEF FINANCIAL OFFICER | Sale (S): 6,247 @ $32.48 · Sale (S): 740 @ $33.12 | EDGAR |
| 2025-04-01 | 4 | Kapadia Sandip — CHIEF FINANCIAL OFFICER | Option exercise (M): 15,000 @ $0 · Tax withholding (F): 8,014 @ $33.19 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2025-03-05 | 4 | Dierks Jeffrey — CHIEF COMMERCIAL OFFICER | Option exercise (M): 4,869 @ $8.22 · Sale (S): 4,369 @ $32.61 · Sale (S): 500 @ $33.23 · Option exercise (M): 4,869 (derivative) @ $0 | EDGAR |
| 2025-01-28 | 4 | Budur Kumar — CHIEF MEDICAL OFFICER | Option exercise (M): 2,187 @ $0 · Tax withholding (F): 1,151 @ $38.01 · Option exercise (M): 2,187 (derivative) @ $0 · Grant/award (A): 37,400 (derivative) @ $0 · Grant/award (A): 10,650 (derivative) @ $0 | EDGAR |
| 2025-01-28 | 4 | Dierks Jeffrey — CHIEF COMMERCIAL OFFICER | Option exercise (M): 13,125 @ $30.69 · Sale (S): 8,000 @ $36.94 · Sale (S): 5,125 @ $37.87 · Option exercise (M): 2,687 @ $0 · Tax withholding (F): 1,058 @ $38.01 · Sale (S): 1,629 @ $38.02 · +4 more | EDGAR |
| 2025-01-28 | 4 | Serafin Andrew — CHIEF STRATEGY OFFICER | Option exercise (M): 2,500 @ $0 · Tax withholding (F): 865 @ $38.01 · Option exercise (M): 2,500 (derivative) @ $0 · Grant/award (A): 36,500 (derivative) @ $0 · Grant/award (A): 10,400 (derivative) @ $0 | EDGAR |
| 2025-01-28 | 4 | Kapadia Sandip — CHIEF FINANCIAL OFFICER | Option exercise (M): 3,812 @ $0 · Tax withholding (F): 2,037 @ $38.01 · Sale (S): 1,775 @ $38.05 · Option exercise (M): 3,812 (derivative) @ $0 · Grant/award (A): 66,250 (derivative) @ $0 · Grant/award (A): 18,900 (derivative) @ $0 | EDGAR |
| 2025-01-28 | 4 | Dayno Jeffrey M. — PRESIDENT, CEO, Director | Option exercise (M): 10,500 @ $0 · Tax withholding (F): 4,567 @ $38.01 · Option exercise (M): 10,500 (derivative) @ $0 · Grant/award (A): 180,000 (derivative) @ $0 · Grant/award (A): 52,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Harmony Biosciences Holdings, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-04 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-16 | 8-K | 2.02 — Results of Operations and Financial Condition 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-14 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-14 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-02 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-24 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-12 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-04 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-23 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=HRMY returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →